START FREE TRIAL
Home Healthcare STERIS plc

STERIS plc

$19.00

SKU: STE Category:

Description

STERIS’ 45.3% Sterilization Margin: A Profitability Powerhouse Facing New Challenges!

 

STERIS plc reported second quarter fiscal 2026 results reflecting a 10% increase in as-reported revenue and a 9% rise in constant currency organic revenue, driven by volume gains and a 210 basis point price contribution. Gross margin expanded by 60 basis points to 44.3%, supported mainly by volume-related productivity improvements that offset inflationary pressures and tariffs. EBIT margin rose 90 basis points to 23.1%, reflecting operating expense leverage across the business. Adjusted earnings per diluted share grew 15% year-over-year to $2.47, while net income from continuing operations reached $244.5 million. Free cash flow for the first half was $527.7 million, marking a strong start to the year and benefiting from working capital improvements and front-loaded earnings. Capital expenditures totaled $180.1 million for the half-year, with $1.9 billion in total debt and a gross-to-EBITDA leverage ratio around 1.2x. Segment performance was mixed but generally positive.